argenx SE (ARGNF)
| Market Cap | 33.25B |
| Revenue (ttm) | 2.64B |
| Net Income (ttm) | 1.06B |
| Shares Out | n/a |
| EPS (ttm) | 15.94 |
| PE Ratio | 31.25 |
| Forward PE | 34.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10 |
| Average Volume | 22 |
| Open | 547.60 |
| Previous Close | 547.18 |
| Day's Range | 547.60 - 547.60 |
| 52-Week Range | 442.89 - 697.42 |
| Beta | 0.04 |
| RSI | 51.33 |
| Earnings Date | Jul 31, 2025 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]
Financial Performance
Financial StatementsNews
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
NEW YORK , July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Dan...
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 2.79% on an annualized basis producing an average annual return of 17.38%. Currently, argenx has a market capitalization of ...
Argenx's CIDP Challenge: A Safety Signal Points To Operational Refinement, Not Ruin
FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls
Argenx SE (NASDAQ: ARGX) stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) signaled serious risks/safety identified by the reporting system for Vyvgart Hytrulo (efgar...
FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls
Argenx SE ARGX stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) signaled serious risks/safety identified by the reporting system for Vyvgart Hytrulo (efgartigimod alf...
argenx down 7% as FDA identifies possible safety signal with Vyvgart Hytrulo
argenx gets EU nod for Vyvgart subcutaneous injection
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
VYVGART ® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDP Approval based on ADHERE clinical trial, the l...
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 6.27% on an annualized basis producing an average annual return of 20.6%. Currently, argenx has a market capitalization of $...
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease
ALKIVIA data demonstrate significant improvement in muscle strength and physical function in myositis patients treated with efgartigimod RHO data show efgartigimod achieved sustained reduction in auto...
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease
ALKIVIA data demonstrate significant improvement in muscle strength and physical function in myositis patients treated with efgartigimod RHO data show efgartigimod achieved sustained reduction in auto...
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
June 3, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today anno...
argenx Announces Results of Annual General Meeting of Shareholders
May 28, 2025 – 10:01 PM C ET
Hot Picks in biotech: argenx, Scholar Rock & Kiniksa
David Nierengarten, senior analyst at Wedbush, shares his hot picks in the biotech sector: argenx SE, Scholar Rock and Kiniksa Pharmaceuticals.
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?
These large-cap stocks were the worst performers in the last week. Are they in your portfolio? argenx SE (NASDAQ: ARGX) shares tumbled 15.40% after the company reported first-quarter results . Vertex...
Argenx Q1 Earnings: Less Than Perfect Report Gets Punished
Argenx targets Vision 2030 with 50,000 patients and 10 labeled indications by 2025
argenx SE (ARGX) Q1 2025 Earnings Call Transcript
Argenx plunges after Q1 revenue miss
Argenx Beats Sales Expectations — But Not By Enough — And Shares Tumble
Argenx stock tumbled Thursday after its drug, Vyvgart, beat sales expectations. But the beat wasn't strong enough for investors.
Earnings Scheduled For May 8, 2025
Companies Reporting Before The Bell • Sempra (NYSE: SRE) is likely to report quarterly earnings at $1.32 per share on revenue of $3.92 billion. • Warner Music Gr (NASDAQ: WMG) is projected to report...
Argenx reports mixed Q1 results; reaffirms FY25 outlook
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
$790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opin...
A Look Into argenx Inc's Price Over Earnings
In the current session, the stock is trading at $622.93, after a 1.27% increase. Over the past month, argenx Inc. (NASDAQ: ARGX) stock increased by 10.42% , and in the past year, by 62.84% . With per...
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
Announcing New $250M Share Repurchase Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million ; Adjusted EBIT...